This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Play Safe! S&P 500 is Teasingly Close to its 50 DMA: 3 Picks
by Tirthankar Chakraborty
With the S&P 500 trading close to its 50-day moving average, it's wise for investors to place bets on safe stocks such as Iron Mountain (IRM), Organon (OGN), and International Business Machines (IBM).
Why HCA Healthcare (HCA) is a Smart Addition to Your Portfolio
by Zacks Equity Research
HCA Healthcare (HCA) remains well-poised for growth on growing patient volumes, buyouts, effective telehealth services and a notable financial stand.
Why the Market Dipped But Organon (OGN) Gained Today
by Zacks Equity Research
In the most recent trading session, Organon (OGN) closed at $18.16, indicating a +1.68% shift from the previous trading day.
Encompass Health (EHC) Plans a 50-Bed Facility to Serve Texas
by Zacks Equity Research
Encompass Health (EHC) unveils plans to build an inpatient rehabilitation hospital in San Antonio to bring improved health outcomes and further fortify its presence in Texas.
UnitedHealth (UNH) to Roll Out Medical Claims Software Soon
by Zacks Equity Research
UnitedHealth (UNH) assists care providers with more than $2 billion through several initiatives to mitigate the cash flow crunch arising from the cyberattack.
Here's Why You Should Retain Centene (CNC) Stock for Now
by Zacks Equity Research
Robust growth outlook, contract wins, accretive acquisitions and streamlining of businesses poise Centene (CNC) well for growth.
Markets Dip but it's Time to Buy These Low-Risk High-Income Stocks
by Shaun Pruitt
Now may be an ideal time to buy these lower-risk, high-income stocks especially as markets start to digest hot inflationary data.
Centene (CNC), Pearl Health Unite to Enhance Value-Based Care
by Zacks Equity Research
Centene (CNC) collaborates with Pearl Health to enhance value-based care services for Medicare Advantage members.
Here's Why You Should Add Cigna (CI) Stock to Your Portfolio
by Zacks Equity Research
Cigna's (CI) strong Evernorth and Cigna Healthcare segments, value enhancing initiatives and a positive 2024 outlook poise it well for growth.
Teladoc Health (TDOC) Unveils Solution to Ease Weight Loss
by Zacks Equity Research
Teladoc Health (TDOC) expands weight management capabilities by coming up with a tailored solution that aims to reduce obesity-related medical care expenses for members.
Cencora, Inc. (COR) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Cencora (COR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Don't Overlook These Low-Risk High-Dividend Yielding Stocks
by Shaun Pruitt
Now looks like a good time to buy these highly ranked stocks with earnings estimate revisions likely to keep ticking up after their favorable Q4 results which makes their high dividend yields and low beta ratios more attractive.
The Zacks Analyst Blog Highlights Booz Allen Hamilton, Tyson Foods, AXIS Capital, First Financial and Organon
by Zacks Equity Research
Booz Allen Hamilton, Tyson Foods, AXIS Capital, First Financial and Organon are included in this Analyst Blog.
Top 5 Low-Beta High-Yielding Stocks to Shield Your Portfolio
by Nalak Das
We have narrowed our search to five low-beta (beta >0 <1) stocks with a solid dividend yield. These are: BAH, AXS, OGN, TSN, FFIN.
Organon (OGN) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Organon (OGN) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Should WisdomTree U.S. SmallCap Dividend ETF (DES) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DES
Is WisdomTree U.S. SmallCap Dividend ETF (DES) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DES
Organon (OGN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Organon (OGN) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Viatris (VTRS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Viatris (VTRS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Organon (OGN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Organon (OGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Life Time Group Holdings, Inc. (LTH) Q3 Earnings Match Estimates
by Zacks Equity Research
Life Time Group Holdings, Inc. (LTH) delivered earnings and revenue surprises of 0% and 0.16%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Organon (OGN) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Organon (OGN) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Organon (OGN) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Organon (OGN) delivered earnings and revenue surprises of 35.05% and 3.10%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Sotera Health Company (SHC) Tops Q2 Earnings Estimates
by Zacks Equity Research
Sotera Health Company (SHC) delivered earnings and revenue surprises of 16.67% and 2.21%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Organon (OGN) Reports Q1 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Organon (OGN) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.